摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(S)-1-pyrrolidin-3-ylmethylmethanesulfonamide | 1219832-13-9

中文名称
——
中文别名
——
英文名称
N-(S)-1-pyrrolidin-3-ylmethylmethanesulfonamide
英文别名
(N-pyrrolidin-3-ylmethyl)methanesulfonamide;(S)-N-(Pyrrolidin-3-ylmethyl)methanesulfonamide;N-[[(3S)-pyrrolidin-3-yl]methyl]methanesulfonamide
N-(S)-1-pyrrolidin-3-ylmethylmethanesulfonamide化学式
CAS
1219832-13-9
化学式
C6H14N2O2S
mdl
——
分子量
178.255
InChiKey
PCAPUMJQKJGNGT-LURJTMIESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    66.6
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS<br/>[FR] BIS-PYRIDYLPYRIDONES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HORMONE DE MÉLANO-CONCENTRATION
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2010141538A1
    公开(公告)日:2010-12-09
    The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1 ), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.
    这项发明提供了新型的双吡啶基吡啉酮,它们是黑素浓集激素受体1(MCHR1)的拮抗剂,包含它们的药物组合物,它们的制备方法,以及它们在治疗和治疗肥胖和糖尿病中的用途。
  • [EN] HETEROCYCLIC ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX HÉTÉROCYCLIQUES
    申请人:HOFFMANN LA ROCHE
    公开号:WO2012020037A1
    公开(公告)日:2012-02-16
    Compounds having the formula (I) wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    具有化学式(I)的化合物,其中R1、R2、R3和X的定义如下,是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
  • BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS
    申请人:Christensen, IV Siegfried Benjamin
    公开号:US20120077794A1
    公开(公告)日:2012-03-29
    The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.
    本发明提供了一种新型的双吡啶基吡啶酮,其为黑色素浓集激素受体1(MCHR1)的拮抗剂,包含它们的制药组合物、制备它们的过程,并用于治疗肥胖症和糖尿病的治疗。
  • Discovery of <i>N</i>-[4-[6-<i>tert</i>-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1<i>H</i>-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase
    作者:Francisco X. Talamas、Sarah C. Abbot、Shalini Anand、Ken A. Brameld、David S. Carter、Jun Chen、Dana Davis、Javier de Vicente、Amy D. Fung、Leyi Gong、Seth F. Harris、Petra Inbar、Sharada S. Labadie、Eun K. Lee、Remy Lemoine、Sophie Le Pogam、Vincent Leveque、Jim Li、Joel McIntosh、Isabel Nájera、Jaehyeon Park、Aruna Railkar、Sonal Rajyaguru、Michael Sangi、Ryan C. Schoenfeld、Leanna R. Staben、Yunchou Tan、Joshua P. Taygerly、Armando G. Villaseñor、Paul E. Weller
    DOI:10.1021/jm401329s
    日期:2014.3.13
    In the past few years, there have been many advances in the efforts to cure patients with hepatitis C virus (HCV). The ultimate goal of these efforts is to develop a combination therapy consisting of only direct-antiviral agents (DAAs). In this paper, we discuss our efforts that led to the identification of a bicyclic template with potent activity against the NS5B polymerase, a critical enzyme on the life cycle of HCV. In continuation of our exploration to improve the stilbene series, the 3,5,6,8-tetrasubstituted quinoline core was identified as replacement of the stilbene moiety. 6-Methoxy-2(1H)-pyridone was identified among several heterocyclic headgroups to have the best potency. Solubility of the template was improved by replacing a planar aryl linker with a saturated pyrrolidine. Profiling of the most promising compounds led to the identification of quinoline 41 (RG7109), which was selected for advancement to clinical development.
  • US8067442B2
    申请人:——
    公开号:US8067442B2
    公开(公告)日:2011-11-29
查看更多